Nurix Therapeutics, Inc.
NASDAQ:NRIX
19.2 (USD) • At close February 5, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 54.549 | 76.987 | 38.627 | 29.75 | 17.82 | 31.115 | 37.449 |
| Cost of Revenue
| 0 | 189.148 | 10.808 | 6.082 | 66.494 | 45.025 | 40.514 |
| Gross Profit
| 54.549 | -112.161 | 27.819 | 23.668 | -48.674 | -13.91 | -3.065 |
| Gross Profit Ratio
| 1 | -1.457 | 0.72 | 0.796 | -2.731 | -0.447 | -0.082 |
| Reseach & Development Expenses
| 221.632 | 189.148 | 184.497 | 116.434 | 66.494 | 45.025 | 40.514 |
| General & Administrative Expenses
| 45.944 | 42.902 | 37.997 | 31.202 | 16.309 | 8.326 | 6.674 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 45.944 | 42.902 | 37.997 | 31.202 | 16.309 | 8.326 | 6.674 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 267.576 | 232.05 | 222.494 | 147.636 | 82.803 | 53.351 | 47.188 |
| Operating Income
| -213.027 | -155.063 | -183.867 | -117.886 | -64.983 | -22.236 | -9.739 |
| Operating Income Ratio
| -3.905 | -2.014 | -4.76 | -3.963 | -3.647 | -0.715 | -0.26 |
| Total Other Income Expenses Net
| 19.728 | 11.115 | 3.507 | 0.823 | 1.206 | 0.776 | 0.818 |
| Income Before Tax
| -193.299 | -143.948 | -180.36 | -117.063 | -63.777 | -21.46 | -8.921 |
| Income Before Tax Ratio
| -3.544 | -1.87 | -4.669 | -3.935 | -3.579 | -0.69 | -0.238 |
| Income Tax Expense
| 0.27 | 0 | -14.315 | 0.131 | -20.535 | 0.239 | 0.507 |
| Net Income
| -193.569 | -143.948 | -166.045 | -117.194 | -43.242 | -21.699 | -9.428 |
| Net Income Ratio
| -3.549 | -1.87 | -4.299 | -3.939 | -2.427 | -0.697 | -0.252 |
| EPS
| -2.88 | -2.65 | -3.42 | -2.73 | -2.76 | -0.56 | -0.59 |
| EPS Diluted
| -2.88 | -2.65 | -3.42 | -2.73 | -2.76 | -0.56 | -0.59 |
| EBITDA
| -213.027 | -141.409 | -173.059 | -111.804 | -62.803 | -19.882 | -6.751 |
| EBITDA Ratio
| -3.905 | -1.837 | -4.76 | -3.963 | -3.647 | -0.639 | -0.18 |